S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

Bibliographic Details
Main Authors:	Elias Jabbour, Hagop Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gomez, Maria Baer, Carlo Gambacorti-Passerini, James Mccloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice Wang, Meliessa Hennessy, Niti Patel, Alexander Vorog, Bingxia Wang, Huilan Yao, Tammie Yeh, Josep Maria Ribera
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967352.68516.d0

Similar Items

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
by: E. Jabbour, et al.
Published: (2022-06-01)

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
by: David Sanford, et al.
Published: (2015-12-01)

The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
by: Aziz Nazha, et al.
Published: (2013-10-01)

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts
by: Preetesh Jain, et al.
Published: (2013-11-01)

P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
by: J. Apperley, et al.
Published: (2022-06-01)

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: Fadi Haddad, et al.
Published: (2023-08-01)

Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies
by: Elias Jabbour, et al.
Published: (2016-12-01)

Ponatinib‐induced ichthyosiform eruption
by: Nicolas Kluger, et al.
Published: (2021-08-01)

Ponatinib: A drug review
by: Hasmukh Jain, et al.
Published: (2019-01-01)

Ponatinib: Harnessing the elixir potential
by: Vishal Jayakar
Published: (2020-01-01)

Isolated Gastric Myeloid Sarcoma: A Case Report and Review of the Literature
by: Pankit Vachhani, et al.
Published: (2014-01-01)

P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB
by: Jorge Cortes, et al.
Published: (2023-08-01)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
by: H. Jonathan G. Lindström, et al.
Published: (2022-03-01)

Significance of Clinical-Pathological Correlation in Ponatinib Reactions
by: Judith Monserrat Corona Herrera, et al.
Published: (2025-01-01)

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
by: Nicholas Short, et al.
Published: (2023-08-01)

Development and targeted use of nilotinib in chronic myeloid leukemia
by: Carmen Fava, et al.
Published: (2008-11-01)

A case of pityriasis rubra pilaris secondary to ponatinib
by: Ariana Nateghi, et al.
Published: (2025-01-01)

Ponatinib treatment promotes arterial thrombosis and hyperactive platelets
by: Alona Merkulova, et al.
Published: (2019-08-01)

Ponatinib in chronic myeloid leukemia: Finally getting it right?
by: Bhausaheb Bagal, et al.
Published: (2020-01-01)

Mutant BCR-ABL clones in chronic myeloid leukemia
by: Michael S. Mathisen, et al.
Published: (2011-03-01)

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions
by: Nicholas J. Short, et al.
Published: (2024-05-01)

Ponatinib-induced pneumonitis with severe acute respiratory distress syndrome
by: Sofia Dinis Ferreira, et al.
Published: (2023-11-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
by: Eudocia Q. Lee, et al.
Published: (2019-10-01)

PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
by: Serap Karaman, et al.
Published: (2021-11-01)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
by: Manu R. Pandey, et al.
Published: (2017-01-01)

Cristina Palmieri, Dentro il lavoro educativo. Pensare il metodo, tra scenario professionale e cura dell'esperienza educativa della formazione, Milano: Franco Angeli, ISBN 8891769525, 204 pagine, 2018
by: Maria Benedetta Gambacorti Passerini
Published: (2018-12-01)

Educating to prevent youth (aged 16–24) mental distress: giving meaning to an educational effort
by: Maria Benedetta Gambacorti-Passerini
Published: (2021-03-01)

S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY
by: N. Short, et al.
Published: (2022-06-01)

P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA
by: Martin C. Müller, et al.
Published: (2023-08-01)

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
by: Anna Franceschino, et al.
Published: (2008-02-01)

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)
by: Kusuma, Frances Karla, et al.
Published: (2023)

Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy
by: Zhuomiao Lin, et al.
Published: (2025-01-01)

Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development
by: Mayara Nascimento, et al.
Published: (2024-10-01)

Ponatinib induced pityriasis rubra pilaris: Case report and review of literature
by: Sejal Jain, et al.
Published: (2023-01-01)

Probable ponatinib-induced papilledema in a patient with acute lymphocytic leukemia
by: Jared A. Moon, et al.
Published: (2023-12-01)

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)
by: Frances Karla Kusuma, et al.
Published: (2023-04-01)

Nicotinamide–Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds
by: Elizabeth Larocque, et al.
Published: (2020-02-01)

Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia
by: Michele Basile, et al.
Published: (2021-07-01)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
by: Iman Abou Dalle, et al.
Published: (2019-11-01)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
by: Bachar Samra, et al.
Published: (2020-06-01)